Non-replacement therapies in the hemophilias: Update

09.00

Fitusiran
Steve Pipe (USA)

09.30

APC Serpin
James Huntington (UK)

10.00

Anti-TFPI
Alan Mast (USA)

10:30

Thrombotic microangiopathy associated with emicizumab: views from an insider
Paul Coppo (France)

11.00

Break

Novel drugs

11.30

Caplacizumab: results of phase II/phase III studies
Marie A. Scully (UK)

12.00

Satellite Lecture (booked)
TBA

12.30

Satellite Lecture (booked)
TBA

13.00

Lunch Satellite Symposium (booked)
TBA

Gene Therapy

14.00

New strategies for a better and safer gene transfer: less immunogenic
Luigi Naldini (Italy)

14.30

Liver toxicity in gene therapy
Amit Nathwani (UK)

15.00

Oral Communications

16.00

Break

Immunotolerance induction in hemophilia (Part I)

16.30

How to maintain tolerance in hemophilia A
Sébastien Lacroix-Desmazes (France)

17.00

How to induce Treg responses in experimental hemophilia A
Roland Herzog (USA)

17.30

Is it important to induce immune tolerance in the era of non-replacement therapies?
Elena Santagostino (Italy)

18.00

Specific Treg therapy for hemophilia inhibitors: CARs versus BARs?
David Scott (USA)

18.30

Walking Poster Session